CHAPTER 10

References

References

1. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53-54. doi: 10.1111/j.1524-4725.2001.00124.x
2. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297-304. doi: 10.1046/j.1365-2133.2001.04018.x.
3. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-189. doi: 10.1111/j.1087-0024.2005.10102.x.
4. Vujovic A, Del Marmol V. The female pattern hair loss: review of etiopathogenesis and diagnosis. Biomed Res Int. 2014;2014:767628. doi: 10.1155/2014/767628.
5. Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 2013;11(4):e9860. doi: 10.5812/ijem.9860.
6. Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. An Bras Dermatol. 2015;90(4):529-543. doi: 10.1590/abd1806-4841.20153370.
7. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5:541-556. doi: 10.2147/IJWH.S49337.
8. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189-199. PMID: 18044135.
9. Chien Yin GO, Siong-See JL, Wang ECE. Telogen effluvium—a review of the science and current obstacles. J Dermatol Sci. 2021;101(3):156-163. doi: 10.1016/j.jdermsci.2021.01.007.
10. Galal SA, El-Sayed SK, Henidy MMH. Postpartum telogen effluvium unmasking additional latent hair loss disorders. J Clin Aesthet Dermatol. 2024;17(5):15-22.

11. Gupta AK, Economopoulos V, Mann A, Wang T, Mirmirani P. Menopause and hair loss in women: exploring the hormonal transition. Maturitas. 2025;198:108378. doi: 10.1016/j.maturitas.2025.108378.
12. Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, Lobo R, Olsen E. Female pattern hair loss and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891. doi: 10.1210/jc.2018-02548.
13. Mirmirani P. Hormones and clocks: do they disrupt the locks? Fluctuating estrogen levels during menopausal transition may influence clock genes and trigger chronic telogen effluvium. Dermatol Online J. 2016;22(5):13030/qt32r353c4.
14. Kuczara A, Waśkiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Trichoscopy of androgenetic alopecia: a systematic review. J Clin Med. 2024;13(7):1962. doi: 10.3390/jcm13071962.
15. Farkas E, Nehorayan I, Hanan R, Kalner S, Tepper K, Marmon S. Untangling estrogen therapy for menopausal hair loss: a systematic review. J Am Acad Dermatol. 2026;95(3):756-758. doi: 10.1016/j.jaad.2026.04.1924.
16. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi: 10.1097/GME.0000000000002028.
17. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatol Ther (Heidelb). 2019;9(1):51-70. doi: 10.1007/s13555-018-0278-6.
18. Cappellini MD, Santini V, Braxs C, Shander A. Iron metabolism and iron deficiency anemia in women. Fertil Steril. 2022;118(4):607-614. doi: 10.1016/j.fertnstert.2022.08.014.
19. Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol Hepatol (N Y). 2015;11(4):241-250.
20. Treister-Goltzman Y, Yarza S, Peleg R. Iron deficiency and nonscarring alopecia in women: systematic review and meta-analysis. Skin Appendage Disord. 2022;8(2):83-92. doi: 10.1159/000519952.
21. Chen Y, Dong X, Wang Y, Li Y, Xiong L, Li L. Serum 25-hydroxyvitamin D in non-scarring alopecia: a systematic review and meta-analysis. J Cosmet Dermatol. 2024;23(4):1131-1140. doi: 10.1111/jocd.16093.

22. Chang HC, Chang YS. Association between serum zinc levels and androgenetic alopecia: a systematic review and meta-analysis. J Cosmet Dermatol. 2022;21(4):1774-1777. doi: 10.1111/jocd.14564.

23. Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169. doi: 10.1159/000462981.

24. Yelich A, Jenkins H, Holt S, Miller R. Biotin for hair loss: teasing out the evidence. J Clin Aesthet Dermatol. 2024;17(8):56-61.

25. Moltó-Balado P, Simeó-Monzo A, del Barrio-Gonzalez A. Effectiveness of biotin supplementation for hair growth in patients with alopecia: a systematic review. Dermato. 2026;6(2):17. doi: 10.3390/dermato6020017.

26. Ylli D, Soldin SJ, Stolze B, Wei B, Nigussie G, Nguyen H, Mendu DR, Mete M, Wu D, Goes-Lima CJ, Klubo-Gwiezdzinska J, Burman KD, Wartofsky L. Biotin interference in assays for thyroid hormones, thyrotropin and thyroglobulin. Thyroid. 2021;31(8):1160-1170. doi: 10.1089/thy.2020.0866.

27. Bowen R, Benavides R, Colón-Franco JM, Katzman BM, Muthukumar A, Sadrzadeh H, Straseski J, Klause U, Tran N. Best practices in mitigating the risk of biotin interference with laboratory testing. Clin Biochem. 2019;74:1-11. doi: 10.1016/j.clinbiochem.2019.08.012.

28. van Beek N, Bodó E, Kromminga A, Gáspár E, Meyer K, Zmijewski MA, Slominski A, Wenzel BE, Paus R. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab. 2008;93(11):4381-4388. doi: 10.1210/jc.2008-0283.

29. Hussein RS, Atia T, Bin Dayel S. Impact of thyroid dysfunction on hair disorders. Cureus. 2023;15(8):e43266. doi: 10.7759/cureus.43266.

30. Cohen B, Cadesky A, Jaggi S. Dermatologic manifestations of thyroid disease: a literature review. Front Endocrinol (Lausanne). 2023;14:1167890. doi: 10.3389/fendo.2023.1167890.

31. Bin Dayel S, Hussein RS, Atia T, Abahussein O, Al Yahya RS, Elsayed SH. Is thyroid dysfunction a common cause of telogen effluvium?: a retrospective study. Medicine (Baltimore). 2024;103(1):e36803. doi: 10.1097/MD.0000000000036803.

32. Lee S, Lee YB, Kim BJ, Lee WS. Screening of thyroid function and autoantibodies in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1410-1413.e4. doi: 10.1016/j.jaad.2018.10.066.

33. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi: 10.1210/clinem/dgad463.

34. Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4(4):203-211. doi: 10.1016/j.ijwd.2018.05.001.

35. Elhassan YS, Hawley JM, Cussen L, Abbara A, Clarke SA, Kempegowda P, Dhillon-Smith RK, Thadani P, Busby M, Owusu-Darkwah L, Marrington R, Duncan WC, Semple RK, Quinton R, O'Reilly MW. Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women. Clin Endocrinol (Oxf). 2025;103(4):540-566. doi: 10.1111/cen.15265.

36. Alhanshali L, Buontempo M, Shapiro J, Lo Sicco K. Medication-induced hair loss: an update. J Am Acad Dermatol. 2023;89(2S):S20-S28. doi: 10.1016/j.jaad.2023.04.022.

37. Zhang D, LaSenna C, Shields BE. Culprits of medication-induced telogen effluvium, part 2. Cutis. 2024;113(1):11-14. doi: 10.12788/cutis.0919.

38. Novo Nordisk Inc. Wegovy (semaglutide) injection and tablets: prescribing information. DailyMed. Section 6.1, hair loss. Accessed October 2, 2026.

39. Eli Lilly and Company. Zepbound (tirzepatide) injection: prescribing information. DailyMed. Section 6.1, hair loss. Accessed October 2, 2026.

40. Billero V, Miteva M. Traction alopecia: the root of the problem. Clin Cosmet Investig Dermatol. 2018;11:149-159. doi: 10.2147/CCID.S137296.

41. Khumalo N, Ngwanya R. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol. 2007;21(3):433-434. doi: 10.1111/j.1468-3083.2006.01933.x.

42. Canfield Scientific. HairMetrix. Canfield Scientific. Accessed October 3, 2026.

43. Özçelik D. Extensive traction alopecia attributable to ponytail hairstyle and its treatment with hair transplantation. Aesthetic Plast Surg. 2005;29(4):325-327. doi: 10.1007/s00266-005-0004-5.

44. Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Alopecia areata: current treatments and new directions. Am J Clin Dermatol. 2023;24(6):895-912. doi: 10.1007/s40257-023-00808-1.

45. Waśkiel A, Rakowska A, Sikora M, Olszewska M, Rudnicka L. Trichoscopy of alopecia areata: an update. J Dermatol. 2018;45(6):692-700. doi: 10.1111/1346-8138.14283.

46. Gregoire S, McIntosh B, Sanchez K, Biba U, Mostaghimi A. Local corticosteroids for alopecia areata: a narrative review. Dermatol Ther (Heidelb). 2025;15(7):1607-1631. doi: 10.1007/s13555-025-01421-2.

47. Kaczorowska A, Rudnicka L, Stefanato CM, Waśkiel-Burnat A, Warszawik-Hendzel O, Olszewska M, Rakowska A. Diagnostic accuracy of trichoscopy in trichotillomania: a systematic review. Acta Derm Venereol. 2021;101(10):adv00565. doi: 10.2340/00015555-3859.

48. Farhat LC, Olfson E, Nasir M, Levine JLS, Li F, Miguel EC, Bloch MH. Pharmacological and behavioral treatment for trichotillomania: an updated systematic review with meta-analysis. Depress Anxiety. 2020;37(8):715-727. doi: 10.1002/da.23028

49. Hill RC, Gold JAW, Lipner SR. Comprehensive review of tinea capitis in adults: epidemiology, risk factors, clinical presentations, and management. J Fungi (Basel). 2024;10(5):357. doi: 10.3390/jof10050357

50. Waśkiel-Burnat A, Rakowska A, Sikora M, Ciechanowicz P, Olszewska M, Rudnicka L. Trichoscopy of tinea capitis: a systematic review. Dermatol Ther (Heidelb). 2020;10(1):43-52. doi: 10.1007/s13555-019-00350-1

51. Wei LW, Qiao JJ. Mini-review: the diagnostic methods of tinea capitis. Mycopathologia. 2023;188(5):563-569. doi: 10.1007/s11046-023-00731-3

52. Kanti V, Röwert-Huber J, Vogt A, Blume-Peytavi U. Cicatricial alopecia. J Dtsch Dermatol Ges. 2018;16(4):435-461. doi: 10.1111/ddg.13498

53. Filbrandt R, Rufaut N, Jones L, Sinclair R. Primary cicatricial alopecia: diagnosis and treatment. CMAJ. 2013;185(18):1579-1585. doi: 10.1503/cmaj.111570

54. Fechine COC, Valente NYS, Romiti R. Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features. An Bras Dermatol. 2022;97(3):348-357. doi: 10.1016/j.abd.2021.08.008

55. Larkin SC, Cantwell HM, Imhof RL, Torgerson RR, Tolkachjov SN. Lichen planopilaris in women: a retrospective review of 232 women seen at Mayo Clinic from 1992 to 2016. Mayo Clin Proc. 2020;95(8):1684-1695. doi: 10.1016/j.mayocp.2020.02.028

56. Gowda SK, Errichetti E, Behera B, Thakur V, Garg S, Sahu DK, Sethy M, Ayyanar P. Trichoscopic features of lichen planopilaris versus frontal

fibrosing alopecia: a systematic review. Dermatol Pract Concept. 2025;15(1):4481. doi: 10.5826/dpc.1501a4481

57. Seyed Jafari SM, Starace M, Katoulis A, et al. Management of classic lichen planopilaris: the EADV Task Force on Hair Diseases position statement. J Eur Acad Dermatol Venereol. 2026;40(8):1306-1317. doi: 10.1111/jdv.70379
58. Kępińska K, Jałowska M, Bowszyc-Dmochowska M. Frontal fibrosing alopecia—a review and a practical guide for clinicians. Ann Agric Environ Med. 2022;29(2):169-184. doi: 10.26444/aaem/141324
59. Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S. Frontal fibrosing alopecia: a review. J Clin Med. 2021;10(9):1805. doi: 10.3390/jcm10091805
60. Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70(4):670-678. doi: 10.1016/j.jaad.2013.12.003.
61. Lis-Święty A, Brzezińska-Wcisło L. Frontal fibrosing alopecia: a disease that remains enigmatic. Postepy Dermatol Alergol. 2020;37(4):482-489. doi: 10.5114/ada.2020.98241.
62. George EA, Matthews C, Roche FC, Taylor SC. Beyond the Hot Comb: Updates in Epidemiology, Pathogenesis, and Treatment of Central Centrifugal Cicatricial Alopecia from 2011 to 2021. American Journal of Clinical Dermatology. 2023;24(1):81-88. doi: 10.1007/s40257-022-00740-w
63. Herskovitz I, Miteva M. Central centrifugal cicatricial alopecia: challenges and solutions. Clinical, Cosmetic and Investigational Dermatology. 2016;9:175-181. doi: 10.2147/CCID.S100816
64. Miteva M, Tosti A. Dermatoscopic features of central centrifugal cicatricial alopecia. Journal of the American Academy of Dermatology. 2014;71(3):443-449. doi: 10.1016/j.jaad.2014.04.069
65. Sperling LC. The role of the scalp biopsy in the evaluation of alopecia. Journal of the American Academy of Dermatology. 2023;89(2S):S16-S19. doi: 10.1016/j.jaad.2023.05.047
66. Seo HM, Oh SU, Kim S, Park JH, Kim JS. Dutasteride in the treatment of frontal fibrosing alopecia: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2024;38(8):1514-1521. doi: 10.1111/jdv.19802
67. Jackson T, Sow Y, Dinkins J, et al. Treatment for central centrifugal cicatricial alopecia: Delphi consensus recommendations. J Am Acad Dermatol. 2024;90(6):1182-1189. doi: 10.1016/j.jaad.2023.12.073

68. Ly N, McClure EM, Hordinsky MK, Farah RS, Park SY. Safety and efficacy of minoxidil treatment in scarring alopecia: a scoping review. J Drugs Dermatol. 2024;23(3):146-151. doi: 10.36849/JDD.7743

69. Ekelem C, Pham C, Atanaskova Mesinkovska N. A systematic review of the outcome of hair transplantation in primary scarring alopecia. Skin Appendage Disord. 2019;5(2):65-71. doi: 10.1159/000492539

70. Rezende HD, Leal TB, Dias MFRG. A systematic review of follicular unit graft survival rates after hair transplantation in primary cicatricial alopecia. Dermatol Surg. 2026;52(7):720-721. doi: 10.1097/DSS.0000000000004911

71. Saqib NU, Bhat YJ, Shah IH, et al. Assessment, reliability, and validity of trichoscopy in the evaluation of alopecia in women. Int J Womens Dermatol. 2021;7(4):458-465. doi: 10.1016/j.ijwd.2021.02.002

72. Inui S. Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J Dermatol. 2011;38(1):71-75. doi: 10.1111/j.1346-8138.2010.01119.x

73. Jackson AJ, Price VH. How to diagnose hair loss. Dermatol Clin. 2013;31(1):21-28. doi: 10.1016/j.det.2012.08.007

74. Rongioletti F, Christana K. Cicatricial (scarring) alopecias: an overview of pathogenesis, classification, diagnosis, and treatment. Am J Clin Dermatol. 2012;13(4):247-260. doi: 10.2165/11596960-000000000-00000

75. Somani N, Bergfeld WF. Cicatricial alopecia: classification and histopathology. Dermatol Ther. 2008;21(4):221-237. doi: 10.1111/j.1529-8019.2008.00203.x

76. Ramos PM, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Female-pattern hair loss: therapeutic update. An Bras Dermatol. 2023;98(4):506-519. doi: 10.1016/j.abd.2022.09.006

77. Jimenez-Cauhe J, Vaño-Galvan S, Mehta N, et al. Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia. J Cosmet Dermatol. 2024;23(11):3767-3773. doi: 10.1111/jocd.16473

78. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. doi: 10.1016/j.jaad.2021.02.054

79. Trüeb RM, Caballero-Uribe N, Luu NNC, Dmitriev A. Serious complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022;30:97-98. doi: 10.1016/j.jdcr.2022.09.035

80. Akiska YM, Mirmirani P, Roseborough I, et al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement. JAMA Dermatol. 2025;161(1):87-95. doi: 10.1001/jamadermatol.2024.4593

81. Werachattawatchai P, Khunkhet S, Harnchoowong S, Lertphanichkul C. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study. Int J Womens Dermatol. 2025;11(3):e227. doi: 10.1097/JW9.0000000000000227

82. Pfizer Inc. Aldactone (spironolactone) tablets: prescribing information. Revised November 2025. Accessed October 5, 2026.

83. Organon LLC. Propecia (finasteride) tablets: prescribing information. DailyMed. Accessed October 5, 2026.

84. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768-776. doi: 10.1067/mjd.2000.107953

85. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142(3):298-302. doi: 10.1001/archderm.142.3.298

86. Oliveira-Soares R, Maia e Silva J, Peres Correia M, André MC. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology. 2013;5(1):22-25. doi: 10.4103/0974-7753.114709

87. Yuan J, He Y, Wan H, Gao Y. Effectiveness of platelet-rich plasma in treating female hair loss: a systematic review and meta-analysis of randomized controlled trials. Skin Res Technol. 2024;30(8):e70004. doi: 10.1111/srt.70004

88. Perez SM, Vattigunta M, Kelly C, Eber A. Low-Level Laser and LED Therapy in Alopecia: A Systematic Review and Meta-Analysis. Dermatol Surg. 2025;51(2):179-183. doi: 10.1097/DSS.0000000000004442

89. Liang X, Chang Y, Wu H, Liu Y, Zhao J, Wang L, Zhuo F. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022;9:905140. doi: 10.3389/fmed.2022.905140

90. U.S. Food and Drug Administration. Microneedling Devices. Updated October 15, 2025. Accessed October 5, 2026.

91. Virtue Labs, LLC. Minoxidil (for women), minoxidil aerosol, foam 5%. Drug Facts labeling. DailyMed, U.S. National Library of Medicine. Updated July 17, 2025. Accessed October 5, 2026.
92. Hamblin MR. Photobiomodulation for the management of alopecia: mechanisms of action, patient selection and perspectives. Clin Cosmet Investig Dermatol. 2019;12:669-678. doi: 10.2147/CCID.S184979
93. Ramos PM, Brianezi G, Martins ACP, da Silva MG, Marques MEA, Miot HA. Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation. Int J Cosmet Sci. 2016;38(6):651-654. doi: 10.1111/ics.12341.
94. Yang X, Qiao R, Cheng W, Lan X, Li Y, Jiang Y. Comparative efficacy of 2% minoxidil alone against combination of 2% minoxidil and low-level laser therapy in female pattern hair loss-A randomized controlled trial in Chinese females. Photodiagnosis Photodyn Ther. 2024;45:103966. doi: 10.1016/j.pdpdt.2024.103966.
95. U.S. Food and Drug Administration. iRestore Hair Growth System. 510(k) Summary K151662. 2015. Accessed October 5, 2026.
96. Wasserbauer S. Wound healing for the hair transplant surgeon. Hair Transplant Forum Int. 2012;22(2):37-44. doi: 10.33589/22.2.0037.
97. Lam SM. Hair Loss and Hair Restoration in Women. Facial Plast Surg Clin North Am. 2020;28(2):205-223. doi: 10.1016/j.fsc.2020.01.007.
98. True RH. Is Every Patient of Hair Loss a Candidate for Hair Transplant?-Deciding Surgical Candidacy in Pattern Hair Loss. Indian J Plast Surg. 2021;54(4):435-440. doi: 10.1055/s-0041-1739247.
99. International Society of Hair Restoration Surgery. Eyebrow & Eyelash Hair Restoration Surgery. Patient information. Accessed October 5, 2026.
100. Marwah MK, Kerure AS, Marwah GS. Microblading and the Science Behind it. Indian Dermatol Online J. 2021;12(1):6-11. doi: 10.4103/idoj.IDOJ_230_20.
101. American Academy of Dermatology Association. A hair transplant can give you permanent, natural-looking results. Patient information. Accessed October 5, 2026.
102. Sun Pharmaceutical Industries, Inc. WINLEVI (clascoterone) cream, 1%: prescribing information. DailyMed, U.S. National Library of Medicine. Updated January 2, 2025.

103. Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294. doi: 10.1111/jdv.17738 . PMID: 34634163.

104. Cosmo Pharmaceuticals N.V. A study to evaluate the efficacy and safety of clascoterone solution in treatment of male pattern hair loss (SCALP 1). ClinicalTrials.gov. NCT05910450.

105. Cosmo Pharmaceuticals N.V. A study to evaluate the efficacy and safety of clascoterone solution in treatment of male pattern hair loss (SCALP 2). ClinicalTrials.gov. NCT05914805.

106. Cosmo Pharmaceuticals N.V. Cosmo announces breakthrough Phase III topline results from SCALP 1 and SCALP 2 for clascoterone 5% solution in male hair loss. Company press release. December 3, 2025.

107. Queen D, Avram MR. Exosomes for treating hair loss: a review of clinical studies. Dermatol Surg. 2025;51(4):409–415. doi: 10.1097/DSS.0000000000004480. PMID: 39447204.

108. Al Ameer MA, Alnajim AT, Al Ameer A, Alsalman Z, Al Ameer GA, Alnajim ST, et al. Exosomes and hair regeneration: a systematic review of clinical evidence across alopecia types and exosome sources. Clin Cosmet Investig Dermatol. 2025;18:2215–2227. doi: 10.2147/CCID.S543451. PMID: 4095542.

109. Ersan M, Ozer E, Akin O, Tasli PN, Sahin F. Effectiveness of exosome treatment in androgenetic alopecia: outcomes of a prospective study. Aesthetic Plast Surg. 2024;48(21):4262–4271. doi: 10.1007/s00266-024-04332-3. PMID: 39174804.

110. U.S. Food and Drug Administration. Consumer alert on regenerative medicine products including stem cells and exosomes. Published July 22, 2020.

111. Kang BY, Li AW, Lee MH, Wong CC, Naseer N, Ibrahim SA, et al. The safety and efficacy of autologous adipose-derived stromal vascular fraction for nonscarring alopecia: A systematic review. *Arch Dermatol Res.* 2022;314(4):349–356. doi: 10.1007/s00403-021-02238-7. PMID: 34014340.

112. Tak YJ, Lee SY, Cho AR, Kim YS. A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell

constituent extract in androgenetic alopecia. *Stem Cells Transl Med.* 2020;9(8):839–849. doi: 10.1002/sctm.19-0410. PMID: 32420695.

113. Butt G, Hussain I, Ahmad FJ, Choudhery MS. Stromal vascular fraction-enriched platelet-rich plasma therapy reverses the effects of androgenetic alopecia. *J Cosmet Dermatol.* 2020;19(5):1078–1085. doi: 10.1111/jocd.13149. PMID: 31541565.

114. Pinto A, Chaffoo RAK, Terskikh AV. The rise of induced pluripotent stem cell approach to hair restoration. Plastic and Reconstructive Surgery. 2021;148(6S):39S–46S. doi: 10.1097/PRS.0000000000008785. PMID: 34847097.

115. Gur-Cohen S, Yang H, Baksh SC, Miao Y, Levorse J, Kataru RP, et al. Stem cell-driven lymphatic remodeling coordinates tissue regeneration. Science. 2019;366(6470):1218–1225. doi: 10.1126/science.aay4509.